InflaRx to Present at Annual SVB Leerink Global Health Conference
08 févr. 2022 07h30 HE
|
InflaRx N.V.
JENA, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
10 janv. 2022 07h30 HE
|
InflaRx N.V.
Regulatory discussions on Phase I program have been initiatedFirst-in-human study expected to start in the second half of 2022 JENA, Germany, Jan. 10, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:...
InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events
05 janv. 2022 08h00 HE
|
InflaRx N.V.
Presentation at J.P. Morgan Healthcare Conference on January 13thCorporate presentation for H.C. Wainwright BioConnect Conference available online starting January 10thCompany to host virtual R&D...
InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa
05 janv. 2022 07h30 HE
|
InflaRx N.V.
Phase III study to include a new primary endpoint, the modified HiSCRNew primary endpoint and Phase III trial design to be discussed in detail at virtual R&D event on February 3rdPhase III program...
InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)
15 nov. 2021 07h30 HE
|
InflaRx N.V.
Proof of concept established for potential of vilobelimab to reduce use of corticosteroids in AAV patients: vilobelimab demonstrated comparable efficacy to standard of careUse of vilobelimab instead...
InflaRx to Present at H.C. Wainwright 7th Annual Israel Conference
11 nov. 2021 07h30 HE
|
InflaRx N.V.
JENA, Germany, Nov. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Reports Third Quarter 2021 Financial & Operating Results
05 nov. 2021 07h30 HE
|
InflaRx N.V.
Feedback received from FDA supportive of new primary endpoint measuring reductions in all three inflammatory Hidradenitis Suppurativa (HS) lesions for Phase III program with vilobelimab in HSIn Phase...
InflaRx to Present at the Credit Suisse 30th Annual Healthcare Conference
03 nov. 2021 07h30 HE
|
InflaRx N.V.
JENA, GERMANY, Nov. 03, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
27 oct. 2021 07h30 HE
|
InflaRx N.V.
6 out of 7 patients (85.7%) showed clinical remission (PGA score ≤ 1) and closure of target ulcer in the highest dose cohortTreatment was well tolerated; no dose-related adverse events observedFinal...
InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19
19 oct. 2021 07h30 HE
|
InflaRx N.V.
Initial portion of the grant amounts to EUR 25.8 millionRemainder of the grant will be awarded in three additional milestone-dependent tranches JENA, Germany, Oct. 19, 2021 (GLOBE NEWSWIRE) --...